While many JAK2 inhibitors are able to achieve normalization of leukocytosis and thrombocytosis, as well as improve symptoms in cancer patients [15, 16], they are less effective in achieving consistent hematologic remissions and reducing JAK2(V617F) allelic burden [15, 17-20]. This evidence concerns the gene JAK2 and Thrombocytosis.